- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04202081
Voices From the Black Community: Hepatitis C Research Participation
Voices From the Black Community: Beliefs and Attitudes on Participating in Research Studies for Chronic Hepatitis C
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Chronic hepatitis C viral (HCV) infection is three times more prevalent in the African American/black (AA) population than in white patients in the U.S.; yet minorities are woefully under-represented in HCV research, particularly in Phase III drug registration trials. A recent systematic review of randomized controlled clinical trials (RCT) of HCV treatments with interferon-based treatments from 2000 to 2011 found that the proportion of African-American patients in RCTs ranged from 0% - 11%. Despite significant increases in efficacy and reductions in adverse events associated with the new direct acting antiviral (DAA) regimens, the proportion of black patients enrolled in Phase II-III DAA registration trials has not increased dramatically and generally ranges from 1%-18%. Because participation rates in medical research do not fully represent the overall U.S. population or prevalence rates among various subgroups, the Food and Drug Administration (FDA) has mandated pharmaceutical companies to improve demographic subgroups included in clinical trials, to identify barriers to subgroup enrollment in clinical trials, and to employ strategies to encourage greater participation.
Enrolling more diverse patients in medical research, especially racial minorities, is a ubiquitous dilemma that has received a fair amount of scientific attention in the last 10 years. This research has found an important role for the perceptions and attitudes that people have about participating in clinical research. Negative perceptions serve as barriers to enrollment in clinical research, while positive attitudes are facilitators of research participation. Additionally, knowledge gaps, patient-provider communication, health literacy, and mistrust of research and scientists are a few of the commonly reported barriers to participation among minority patients. To our knowledge, no study has been undertaken with black patients with HCV to understand their specific attitudes and perspectives related to participation in HCV-related health or medical research. This information is a prerequisite to developing effective approaches to increasing participation of the black community in HCV-related health or medical research.
Two hundred Black patients will be recruited. Patients who participated in The Patient-Reported Outcomes Project of HCV-TARGET ("PROP UP TARGET") study will be invited to participate. Patients will also be recruited from liver clinics at one medical center. Patients will respond to several survey questions over the phone or in person related to WTP and attitudinal factors related to clinical research.
Participant responses and characteristics will be summarized using graphical and tabular descriptive statistical methods such as sample means, percentiles, frequencies, proportions and standard deviations. All statistical estimates will be reported with confidence intervals.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- University of North Carolina at Chapel Hill
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria
- Previous enrollment in the Patient-Reported Outcomes Project (PROP UP) or recruited from HCV Liver Clinics at the University of North Carolina.
- Self-identified as African-American or Black during the PROP UP study or in-person
- Provide written or verbal permission to be contacted about future research studies
Exclusion Criteria
- Express unwillingness to be contacted about future studies
- Withdrew from PROP UP post-enrollment (eg. death, patient withdrawal)
- Unwilling or unable to provide verbal consent
- Identifies during the phone survey or in-person that he/she is not African-American or Black
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall Willingness to Participate (WTP) Mean Score
Tidsramme: through study completion, an average of 1 day
|
Overall Willingness to Participate Scale (WTP): WTP in research studies was evaluated using 13 items to assess WTP in different types of health/medical research studies.
Responses were based on a five-point Likert scale from 1 (not at all willing) to 5 (very willing), with 3 connoting "unsure/neutral."
The overall WTP score will be calculated for each participant by taking the mean of the 13 items.
Higher scores indicate higher WTP.
|
through study completion, an average of 1 day
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Perceived Benefits/Advantages of Participating in Health/Medical Research Mean Score
Tidsramme: through study completion, an average of 1 day
|
Perceived Benefits Scale: Patients respond to 16 items regarding perceived benefits or advantages of research participation.
Each item is rated on a 5 point likert scale: 1=strongly disagree, 2=disagree, 3=unsure, 4=agree, 5=strongly agree.
The average of all items will be used to create the total mean benefit score.
Higher scores indicate higher Perceived Benefits.
|
through study completion, an average of 1 day
|
Perceived Barriers/Disadvantages of Participating in Health/Medical Research Mean Score
Tidsramme: through study completion, an average of 1 day
|
Perceived Barriers Scale: Patients respond to 12 items regarding barriers or disadvantages of research participation.
Each item is rated on a 5 point likert scale: 1=strongly disagree, 2=disagree, 3=unsure, 4=agree, 5=strongly agree.
The average of all items will be used to create the total mean barrier score.
Higher scores indicate higher Perceived Barriers.
|
through study completion, an average of 1 day
|
Perceived Trust in Doctors Mean Score
Tidsramme: through study completion, an average of 1 day
|
Trust in Doctors Scale: Patients respond to 12 items regarding their trust or mistrust in their medical providers.
Each item is rated on a 5 point likert scale: 1=strongly disagree, 2=disagree, 3=unsure, 4=agree, 5=strongly agree.
Negative items were reverse scored.
The average of all items will be used to create the total mean trust score.
Higher scores indicate higher Perceived Trust.
|
through study completion, an average of 1 day
|
Perceived Health Literacy Mean Score
Tidsramme: through study completion, an average of 1 day
|
Perceived Health Literacy Scale: Three items assessed the health literacy of participants with a five-point response scale: 1 (Never), 2 (Rarely), 3 (Sometimes), 4 (Often), 5 (Always).
Participants were asked (a) how frequently they asked others to help them read medical materials, (b) if they felt uncomfortable filling out medical forms, and (c) if they did not understand their medical condition due to difficulty reading medical materials.
The average of all items will be used to create the total mean health literacy score.
Lower scores indicate higher Perceived Health Literacy.
|
through study completion, an average of 1 day
|
Subjective Knowledge of Health/Medical Research Mean Score
Tidsramme: through study completion, an average of 1 day
|
Subjective Knowledge Scale: Participants were asked how well they felt they understood what health/medical research involved.
This was assessed on a five-point response scale: 1 (Not at all), 2 (Not too well), 3 (Somewhat well), 4 (Pretty well), 5 (Very well).
The average of all items will be used to create the total mean subjective knowledge score.
Higher scores indicate higher subjective knowledge.
|
through study completion, an average of 1 day
|
Objective Knowledge of Health/Medical Research Mean Score
Tidsramme: through study completion, an average of 1 day
|
Objective Knowledge Scale: Knowledge of clinical trials was measured with 10 true/false questions about aspects of clinical trials.
The proportion of correct responses per patient will be recorded.
Higher proportion indicates higher objective knowledge.
|
through study completion, an average of 1 day
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of Participant Recommendations for Strategies
Tidsramme: through study completion, an average of 1 day
|
Open-ended qualitative question to solicit participants' recommendations for strategies to enhance racial diversity in HCV-related research studies.
Responses will be categorized into different recommendation strategies and proportion of patients who listed a strategy in that category will be reported.
|
through study completion, an average of 1 day
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Donna M Evon, PhD, University of North Carolina, Chapel Hill
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Leversykdommer
- Flaviviridae-infeksjoner
- Hepatitt, viral, menneskelig
- Enterovirusinfeksjoner
- Picornaviridae-infeksjoner
- Hepatitt, kronisk
- Hepatitt
- Hepatitt A-virus
- Hepatitt C
- Hepatitt C, kronisk
Andre studie-ID-numre
- 18-0662
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hepatitt C, kronisk
-
Clínica de Oftalmología de Cali S.AFullførtMeibomian kjerteldysfunksjon | Eyes Dry ChronicColombia
-
Alcon ResearchFullført
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgia
-
Dokuz Eylul UniversityEge UniversityFullførtMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CTyrkia
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTilbaketrukketKronisk hepatitt C virusinfeksjonIsrael
-
Hadassah Medical OrganizationUkjentKronisk hepatitt C virusinfeksjonIsrael
-
Beni-Suef UniversityFullførtٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin og HCV genotype 4-infiserte egyptisk erfarne deltakereKronisk hepatitt C virusinfeksjonEgypt
-
Tripep ABInovio PharmaceuticalsUkjentKronisk hepatitt C virusinfeksjonSverige
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C genotype 1 | Hepatitt C (HCV) | Hepatitt C viral infeksjonForente stater, New Zealand
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C (HCV) | Hepatitt C genotype 4 | Hepatitt C viral infeksjonForente stater